What is Biogen's biggest product?
Biogen’s product portfolio includes several key therapies, particularly for multiple sclerosis and spinal muscular atrophy. Its primary treatments include dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), which collectively accounted for 45% of the company's 2024 revenues. Additionally, the company markets nusinersen (Spinraza) for the treatment of spinal muscular atrophy. While these products represent the company's primary revenue drivers, specific rankings of "biggest" by volume or revenue often fluctuate based on quarterly financial reporting and market competition.
Related FAQs
Evaluating whether Biogen Inc. (traded under the ticker BIIB) represents a favorable investment involves examining its prominent market position in neuroscience, biotechnology, and rare disease therapeutics.
Public opinion among Jewish populations regarding the State of Israel is nuanced and depends significantly on geographic location, religious affiliation, and generational factors.
Biogen Inc., trading under the stock ticker BIIB, is a pioneering multinational biotechnology enterprise that discovers, develops, and delivers advanced therapeutic medicines for the treatment of severe neurological and neurodegenerative diseases.
Biogen Inc. involves navigating high-risk biotechnology and pharmaceutical clinical development challenges.
Determining whether Biogen Inc. (traded under the ticker BIIB) is a sound investment involves weighing its established leadership in neuroscience and biotechnology against pipeline execution risks and shifting pharmaceutical revenue streams.
Yes, Bilibili collects user data, which is standard practice for digital platforms to provide and improve their services.
Executive compensation for the chief executive officer guiding Black Hills Corporation (a regulated electric and natural gas utility serving customers across several Midwestern and Western states) reflects utility sector governance standards.
Warren Buffett does not hold shares of Broadcom within Berkshire Hathaway's investment portfolio.
Biogen has implemented targeted workforce rationalizations and localized headcount adjustments, primarily tied to operational restructuring programs, pipeline prioritization choices, and post-acquisition integration initiatives.
Bitcoin and other cryptocurrencies are treated primarily as property rather than fiat currency by major tax authorities like the US Internal Revenue Service.
Identifying premier biotechnology equities to acquire requires focusing on companies with late-stage clinical pipelines, de-risked commercial products, and strong balance sheets.
Biogen is widely regarded as a significant employer in the biotechnology industry, offering compensation packages that are generally competitive with other major pharmaceutical firms.
BlackRock is a top institutional shareholder in the Brunswick Corporation. As of March 2026, BlackRock holds approximately 9.5% of the company's outstanding shares, making it a prominent investor among a diverse group of institutional stakeholders.
No, BioMarin Pharmaceutical does not pay a dividend.
Warren Buffett and his investment conglomerate, Berkshire Hathaway, historically focus their equity investments on stable consumer brands, insurance, railroads, and technology giants like Apple rather than speculative biotechnology or early-stage pha...
Wall Street financial research analysts tracking Biogen Inc. (NASDAQ: BIIB) predominantly maintain a consensus "Hold" rating on the stock, accompanied by selective buy recommendations from institutional healthcare specialists.